This second revision of a competitive renewal application is based on an in-depth analysis of the mechanism(s) of tumor protection in tolerant mice where protection is initiated by CD4 T cell immunity against MUC.1. At the present time there are no reports showing that CD4 T cell tolerance against MUC.1 can be broken by specific vaccination, nor that CD4 T cell immunity generates tumor protection. Therefore, our model is new. Our studies are based on the induction of CD4 T cell responses against a sub-immunogenic T cell determinant of MUC,1 that exploits a new method to """"""""jump-start"""""""" weak Th cell responses, Th-Th cooperation. The method of immunization is also new lymphocytes transgenic for a gene engineered with the two Th cell determinants involved in Th-Th cooperation. Working in MUC.1 transgenic mice during the past two and half years we have been able to show that Th-Th cooperation combined with transgenic lymphocyte immunization (TLI) effectively breaks self tolerance and induce protective immunity. In the experiments proposed in this competitive renewal our goal is to elucidate and understand the mechanism(s) of tumor protection in vivo. Specifically, we will revisit the role of MUC.1 reactive CD4 T cell and assess a potential contribution of CD8 T cells (Aim 1), including the role of central memory and effective memory CD4 and CD8 T cells (Aim 2). In a systematic step-wise approach, we will also study the contribution of bone marrow-derived dendritic cells (DC) and plamacytoid DC (pDC) (Aim 3), and see if activation of NK and NKT cells is part of the overall mechanism of protection (Aim 4). It is hoped that these studies will shed light on the relationship between immunity and protection, and will establish the ground rules for successful intervention against cancer expressing MUC.1 in humans. ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Welch, Anthony R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Internal Medicine/Medicine
Schools of Medicine
La Jolla
United States
Zip Code
Cortez-Gonzalez, Xochitl; Pellicciotta, Ilenia; Gerloni, Mara et al. (2006) TLR9-independent activation of B lymphocytes by bacterial DNA. DNA Cell Biol 25:253-61
Koch, Katherine S; Son, Kyung-Hwa; Maehr, Rene et al. (2006) Immune-privileged embryonic Swiss mouse STO and STO cell-derived progenitor cells: major histocompatibility complex and cell differentiation antigen expression patterns resemble those of human embryonic stem cell lines. Immunology 119:98-115
Gerloni, Mara; Castiglioni, Paola; Zanetti, Maurizio (2005) The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice. J Immunol 175:6551-9
Zanetti, Maurizio (2005) T for two: when helpers need help. Autoimmun Rev 4:571-8
Gerloni, Mara; Zanetti, Maurizio (2005) CD4 T cells in tumor immunity. Springer Semin Immunopathol 27:37-48
Gerloni, Mara; Rizzi, Marta; Castiglioni, Paola et al. (2004) T cell immunity using transgenic B lymphocytes. Proc Natl Acad Sci U S A 101:3892-7
Filaci, G; Gerloni, M; Rizzi, M et al. (2004) Spontaneous transgenesis of human B lymphocytes. Gene Ther 11:42-51
Zanetti, Maurizio; Castiglioni, Paola; Rizzi, Marta et al. (2004) B lymphocytes as antigen-presenting cell-based genetic vaccines. Immunol Rev 199:264-78
Castiglioni, Paola; Gerloni, Mara; Zanetti, Maurizio (2004) Genetically programmed B lymphocytes are highly efficient in inducing anti-virus protective immunity mediated by central memory CD8 T cells. Vaccine 23:699-708
Castiglioni, Paola; Lu, Christina; Lo, David et al. (2003) CD4 T cell priming in dendritic cell-deficient mice. Int Immunol 15:127-36

Showing the most recent 10 out of 15 publications